https://doi.org/10.55788/68ed890a
Haemorrhage is an important adverse event of gastric ESD, potentially obscuring the view of the surgeon during the procedure. Some operators use epinephrine during gastric ESD due to its vasoconstrictive effects. However, no evidence is available to support the use of this substance for this purpose. Dr Hon Chi Yip (The Chinese University of Hong Kong, China) presented the findings of a double-blind, multicentre, randomised-controlled trial that evaluated the efficacy of epinephrine during gastric ESD [1].
The study involved 774 adults diagnosed with gastric mucosal neoplasia, excluding those with multiple lesions or on certain anticoagulants. Participants were divided into 2 groups: 1 received an epinephrine-added solution, and the control group did not. The study’s primary outcome was the duration of the procedure, from the initial mucosal incision to the completion of resection, and secondary outcomes included intra-operative haemorrhage and post-procedure adverse events.
The epinephrine-enhanced solution significantly reduced the procedure time (59.96 minutes in the epinephrine arm vs 68.06 minutes in the control arm; P=0.018) and the number of intra-operative bleeding episodes (mean 1.76 in the epinephrine arm vs 3.02 in the control arm; P<0.001). “The addition of epinephrin significantly shortened the procedural time by about 10% and reduced the need for intraoperative haemostasis,” said Dr Yip.
The study advocates for the routine inclusion of epinephrine in the injection solutions used in gastric ESD procedures, representing an advancement in the field.
- Yip HC, et al. Epinephrine added solution significantly reduced procedural time during gastric endoscopic submucosal dissection (ESD) – results from an international double blinded multi-centre randomized controlled trial. LB11, UEG Week 2023, 14–17 October, Copenhagen, Denmark.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Artificial intelligence-aided colonoscopy did not improve outcomes in Lynch syndrome Next Article
European CRC screening needs to be revised »
« Artificial intelligence-aided colonoscopy did not improve outcomes in Lynch syndrome Next Article
European CRC screening needs to be revised »
Table of Contents: UEGW 2023
Featured articles
SEQUENCE: Risankizumab doubles endoscopic remission rates compared with ustekinumab in CD
What’s New in Artificial Intelligence
Digital intervention relieves symptoms and improves QoL in IBS
GastroGPT: Successful proof-of-concept study of gastroenterology-specific large language model
Other Therapeutics and Outcomes
Primary results from MAESTRO-NASH trial: resmetirom efficacious for NASH
Apraglutide: Advancing the treatment of short bowel syndrome
Endobiliary radiofrequency ablation in pCCA: a pilot study
Raising awareness for microscopic colitis: disease course and predictors
Outcomes of IBD Trials
DIVERSITY1: Filgotinib results in Crohn’s disease leave investigators puzzled
SEQUENCE: Risankizumab doubles endoscopic remission rates compared with ustekinumab in CD
Guselkumab provides benefits in UC regardless of advanced therapy history
INSPIRE: Risankizumab meets all efficacy endpoints in UC
Risankizumab resolves extraintestinal manifestations in CD
Obefazimod takes the spotlight as promising UC treatment
Rapid response to upadacitinib boosts outcomes in severe Crohn’s disease
LUCENT trials: Mirikizumab works in UC, regardless of targeted therapy history
ARTEMIS-UC: New kid in town for UC
Breakthroughs in Colorectal Lesions
Safer removal of large polyps with cold snare technique
Higher recurrence rates with cold snare EMR than with conventional EMR
How to deal with at-risk patients above the CRC screening age limit?
European CRC screening needs to be revised
Advances in Upper Endoscopy and Colonoscopy
Epinephrine boosts efficiency in gastric ESD
Artificial intelligence-aided colonoscopy did not improve outcomes in Lynch syndrome
Can computer technology improve our everyday colonoscopy results?
Is AI-assisted colonoscopy ready for clinical practice?
Should we use E-SEMS or EVT for traumatic oesophageal perforations?
Related Articles
April 14, 2020
Open-label extension study of risankizumab: final results
March 12, 2021
Zanidatamab provides ORR in HER2+ biliary tract cancer
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com